In Restem, LLC v. Jadi Cell LLC, the Federal Circuit affirmed the PTAB's decision, ruling that Restem failed to prove the unpatentability of Jadi Cell's stem cell patent. The court found no errors in the PTAB's claim construction and reiterated that the anticipation analysis for product-by-process claims should not be conflated with infringement analysis. This ruling emphasizes the importance of maintaining distinct legal standards in patent challenges, ensuring that innovations in biotechnology continue to receive protection under patent law.
The Federal Circuit upheld the PTAB's finding that Restem could not prove the invalidity of Jadi Cell's stem cell patent claims, thus protecting intellectual property.
Restem's argument conflated anticipation analysis for product-by-process claims with infringement analysis, leading to a dismissal of their challenges based on prior art.
Collection
[
|
...
]